![]() Nine studies reported one hundred and twenty-three adverse events, twenty-six of which occurred in the treatment groups and ninety-seven in the control groups.Ĭonclusion: Very low to low quality of evidence suggests that HMs seem to produce superior treatment responses for ALS without increased risk of adverse events. For ameliorating motor neuron loss, Jiweiling injection was favoured, but the evidence was very low quality. For delaying activity limitation, Jiweiling injection (MD, 2.84 95% CI, 1.21 to 4.46 p = 0.0006) and Shenmai injection (SMD, 1.07 0.69 to 1.45 p < 0.00001) were significantly more efficacious than Riluzole, but the evidence was low quality. were commonly used in nine, eight, and six trials, respectively. Fourteen HMs (fifty-one single botanicals) were involved Astragalus mongholicus Bunge, Atractylodes macrocephala Koidz., and Glycyrrhiza glabra L. Of these, only five studies were double-blinded, and two were placebo-controlled. Results: Twenty studies ( N = 1,218) were eligible. The primary outcome was the activity limitation measured by validated tools, such as the revised ALS Functional Rating Scale. Forest plots were constructed to assess the effect size and corresponding 95% CIs using fixed-effect models, and random-effect models were employed when required. ![]() ![]() Certainty of evidence was assessed as per the GRADE criteria. The risk of bias was evaluated using the Cochrane’s tool. Per the PRISMA guidelines, trials were identified and extracted. Nine databases and six registers were searched from their inception dates to 25 March 2022. Methods: Randomised controlled trials (RCTs) that investigated the efficacy of HMs in ALS patients compared to any types of controls were identified. We aimed to systematically review the literature pertaining to the effects and safety of HM in ALS. Clinical trials investigating HMs continue however, the use of HM is still questioned. 5Neurological Laboratory of Hebei Province, Shijiazhuang, Chinaīackground: The effect of herbal medicine (HM) on amyotrophic lateral sclerosis (ALS) is controversial.4Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.2Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China.1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. ![]() He is faculty advisor for the UW ISPOR Student Chapter, and is ISPOR President-elect for 2016-17.Yuebo Song 1,2, Qiuyang Jia 1,2, Xiaorui Guan 1,2, Sugimoto Kazuo 1,2,3, Jia Liu 1,2, Weisong Duan 4,5, Luda Feng 1,2, Chi Zhang 1* and Ying Gao 1,2* He co-chaired two ISPOR Good Practice Task Forces-on Real-World Data and on Performance-Based Risk-Sharing Arrangements, and he chaired the ISPOR Health Science Policy Council from 2012 to 2015. Garrison served on the ISPOR Board of Directors. His research interests include national and international health policy issues related to personalized medicine, benefit-risk analysis, insurance, pricing, reimbursement, and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer.įrom 2007-2009, Dr. He has more than 100 publications in peer-reviewed journals. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. From 2002-2004, he was Vice President/Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals in Basel, Switzerland.ĭr. He also co-directs the Global Medicines Program in Global Health. Garrison, PhD, is Professor in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004.
0 Comments
Leave a Reply. |